BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,790,000 shares, an increase of 21.8% from the January 31st total of 1,470,000 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 1.7 days.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BIVI. Geode Capital Management LLC grew its stake in BioVie by 223.3% during the fourth quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after purchasing an additional 85,234 shares during the period. Millennium Management LLC acquired a new position in shares of BioVie during the fourth quarter valued at about $245,000. Drive Wealth Management LLC bought a new position in shares of BioVie during the 4th quarter worth about $120,000. Bank of Montreal Can acquired a new stake in shares of BioVie in the 4th quarter valued at about $100,000. Finally, Sanders Morris Harris LLC bought a new stake in BioVie in the 4th quarter valued at about $85,000. 4.59% of the stock is owned by institutional investors.

BioVie Trading Up 2.5 %

Shares of BIVI stock opened at $1.22 on Thursday. BioVie has a 1-year low of $1.04 and a 1-year high of $9.25. The stock has a market cap of $22.51 million, a price-to-earnings ratio of -0.12 and a beta of 0.51. The stock has a 50-day moving average of $1.87 and a 200-day moving average of $2.28.

BioVie (NASDAQ:BIVI) last released its earnings results on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.